CTLA4 and acute kidney injury: For ICI-associated AKI, only anti-CTLA-4/PD-1 combination therapy use was significantly associated with the outcome (sHR 3.36; 95% CI, 1.15–9.80, P = 0.03) (Figure 2, Supplementary Table S2).